Olutasidenib
Overview
Olutasidenib is a potent and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), an enzyme involved in cellular metabolism which is often mutated in cancer. It is being investigated in the treatment of various cancers, including acute myeloid leukemia (AML) and cholangiocarcinoma.
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Olutasidenib expires 12 Nov 2039 and exclusivity 1 Dec 2029. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Olutasidenib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.